Brexanolone (Zulresso) is approved for postpartum depression.

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Study for the PANCE Precision Exam. Improve with flashcards and multiple choice questions, each question has hints and explanations. Get ready for your exam!

Multiple Choice

Brexanolone (Zulresso) is approved for postpartum depression.

Explanation:
Brexanolone (Zulresso) is approved for postpartum depression. It’s a neurosteroid that modulates GABA-A receptors and was developed specifically to treat postpartum depression in adults. The FDA approval designates this indication and requires administration as a 60-hour IV infusion in a monitored healthcare setting due to risks like substantial sedation or loss of consciousness, especially when combined with other central nervous system depressants. Because the label covers postpartum depression in adults (not a broad, non-specific postpartum mood issue and not limited only to the most severe cases), the statement is true.

Brexanolone (Zulresso) is approved for postpartum depression. It’s a neurosteroid that modulates GABA-A receptors and was developed specifically to treat postpartum depression in adults. The FDA approval designates this indication and requires administration as a 60-hour IV infusion in a monitored healthcare setting due to risks like substantial sedation or loss of consciousness, especially when combined with other central nervous system depressants. Because the label covers postpartum depression in adults (not a broad, non-specific postpartum mood issue and not limited only to the most severe cases), the statement is true.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy